Very interesting point. That makes a lot of sense. Otherwise why didn’t she just wait to join the board until they were accepted onto a major exchange, as they originally reported she would. Naturally we are left guessing and making assumptions because Michaels says things like the “the press release is self explanatory” as he states to me without any clarification from the initial PR about her. Regardless, I am glad she is joining the board and will lead clinical development of their drugs.
It could be that there is work/projects where they need her expertise as they prepare for funding so Dr. Heath went ahead and joined the board. Time will tell but hopefully we are close.
News 
Market Data 
Discover 
AI
